A CD22-directed Car that has had several owners will next year deliver its most important dataset.

The group touts a 72% ORR with SCIB1, but full Scope data have been pushed back into 2025.

A 5% response rate with IMA402 monotherapy seems unlikely to turn heads.

NXP800 yields neither severe thrombocytopenia, nor any responses.

For $500m the big pharma group secures LaNova's anti-VEGF x PD-1 antibody.

First-gen drugs feature in BCL-2 combos, while Jaypirca and BTK degraders apply extra pressure.